Latest News

  • PARTNERSHIPS

    7 Apr 2026

    Insilico Does the Math, Lilly Writes the Check

  • INVESTMENT

    6 Apr 2026

    Meet the Startup Trying to Out-Ozempic Ozempic

  • PARTNERSHIPS

    31 Mar 2026

    The Shot Is So Last Year. Lilly Wants You to Pop a Pill

  • REGULATORY

    26 Mar 2026

    Wegovy Turns Up the Dial and Takes Aim at Lilly

Oral Obesity Pill Push Draws $287M Bet

White tablets stacked on US dollar bill

INVESTMENT

23 Mar 2026

Corxel secures $287M to advance its oral GLP-1 pill CX11 through US and global trials as demand for needle-free options rises

Logo of the Coalition for Metabolic Health displayed over imagery of nutritional and health-related elements

PARTNERSHIPS

2 Dec 2025

Metabolic Care Gets a National Wake Up Call

New US metabolic alliance pushes earlier care and integrated treatments; firms like Lilly and Novo Nordisk should prepare for shifting sta...

Bathroom scale with measuring tape on tiled floor symbolising weight management

INVESTMENT

1 Dec 2025

A MASH Contender Puts Roche in the Spotlight

Roche’s move to acquire 89bio boosts a leading MASH therapy and opens new partnership opportunities across metabolic medicine

Roche corporate sign in front of modern office building on a clear day

PARTNERSHIPS

25 Nov 2025

Pharma Giants Chase the Next Liver Breakthrough

Novo and Roche spark a US push for new metabolic liver treatments as combo strategies take hold

3D rendering of a metabolic cell structure surrounded by blood components.

INSIGHTS

24 Nov 2025

Beyond GLP1: A New Race to Fix the Body’s Fuel System

OrsoBio pursues deeper metabolic repair beyond GLP-1 drugs, signaling a shift toward long-term health gains; investors should watch emergi...

Wegovy vial and syringe beside a stylized model of metabolic liver and fat cells.

REGULATORY

20 Nov 2025

FDA Nod for Metabolic-Liver Therapy Reshapes Treatment Horizon

FDA expands Wegovy to MASH, potentially expanding the metabolic liver disease market and influencing developer strategy

Red-yellow capsules on a high-tech circuit board symbolizing oral metabolic drug innovation.

PARTNERSHIPS

18 Nov 2025

New Partnership Accelerates Push for Oral Metabolic Breakthroughs

Deep Apple Therapeutics and Novo Nordisk team on a non incretin oral target, stirring new momentum in metabolic research

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.